Context: In a previous community-based, cross-sectional study, males with type 1 diabetes (T1D) had lower bone mineral density (BMD) than did matched people without diabetes but females with T1D had normal BMD.
A lthough the relationship between diabetes, bone structure and metabolism, and fractures appears complex and is incompletely understood (1-3), epidemiologic studies consistently indicate that there is around a sixfold increase in the risk of hip fracture in patients with type 1 diabetes (T1D) compared with age-and sexmatched individuals from the general population (4-7). The factors underlying this increased risk include those specific to bone [reduced bone mineral density (BMD) and impaired quality] as well as extraskeletal complications (sensory and autonomic neuropathy, visual impairment, and hypoglycemia) that increase the risk of falls (4, 5, 8, 9) .
Most (4) but not all (10, 11) studies have shown a reduction in BMD in T1D, with some reporting a greater decrease in men than women (12) (13) (14) . A low BMD in T1D has also been linked to a younger age at diagnosis, longer diabetes duration, poor glycemic control, microvascular complications, and high subcutaneous insulin doses (3, 8, (15) (16) (17) . Most of these associations have, however, been found in cross-sectional rather than longitudinal studies, which restricts the clinical inferences that can be drawn.
We have reported previously that community-based adult males but not females with T1D have reduced BMD at the hip, femoral neck, and spine compared with matched controls (14) . The aim of the current study was to reassess the patients with diabetes recruited to the original cross-sectional study after a mean of 10 years to determine whether (1) the BMD in males continued to decline with time, (2) the apparently neutral effect of T1D on BMD in females persisted, and (3) temporal changes in BMD reflected changes in clinical features and bone turnover markers.
Materials and Methods

Patients and approvals
The 102 participants with T1D in the initial cohort (14) were recruited in 2005 to 2006 from Fremantle Hospital outpatient clinics, the Fremantle Diabetes Study cohort (18) , and local private specialist clinics in the Fremantle Hospital catchment area that surrounds the port of Fremantle in the state of Western Australia. Eligibility criteria comprised age $18 years, a confirmed diagnosis of T1D based on history (including insulin requirement from diagnosis) and available laboratory tests (including islet autoantibodies and serum C-peptide), no history of osteoporosis or use of medications for treatment of osteoporosis such as bisphosphonates, and no history of a medical condition or therapy that could impact bone metabolism such as chronic renal impairment or chronic corticosteroid treatment. All recruited patients were invited to participate in a follow-up study in 2015 to 2016 involving the same procedures as the original study. The current study was approved by the Southern Metropolitan Health Service Human Research Ethics Committee, and written informed consent was obtained from each participant before recruitment.
Clinical and laboratory assessment
All participants completed a self-administered questionnaire covering diabetes management and complications, as well as risk factors for, and comorbidities associated with, osteoporosis, including menopausal status in the females. A history of fracture was also obtained. A physical examination was performed including anthropometric measures and assessment of peripheral arterial and sensory nerve function (18) . Fasting morning blood and urine samples were collected and serum glucose, calcium, phosphate, albumin, alkaline phosphatase (ALP), and urine creatinine measured using standard colorimetric and enzymatic methods on a Cobas Integra 800 analyzer (Roche Diagnostics, North Ryde, NSW, Australia). HbA 1c , urine albumin, and urine creatinine were measured immunoturbidimetrically using the same system (14) . The estimated glomerular filtration rate (eGFR) was calculated from the serum creatinine (19) . Complications of diabetes were identified from clinical and laboratory data based on standardized criteria (14, 20) .
Biochemical tests relevant to bone metabolism were performed in the same nationally accredited laboratory as the original study with calibration equations applied when necessary to standardize all concentrations to those at the follow-up assessment (21) . Plasma 25-hydroxy vitamin D was measured by radioimmunoassay. Plasma PTH, serum b carboxyl-terminal type I collagen telopeptide (CTX), total procollagen type 1 N propeptide (P1NP), and osteocalcin were measured by chemiluminescent immunoassay on a Cobas E601 immunoassay analyzer (Roche Diagnostics). Between-run imprecision for all methods was ,3.5%, except for urine albumin, for which it was ,5.0%.
Bone mineral densitometry
The BMD at total hip, femoral neck, lumbar spine (L1 to L4), and distal one-third of forearm was measured using dualenergy X-ray absorptiometry (DXA) on a 4500-W fan beam densitometer (Hologic Corporation, Waltham, MA) in the original study (14) and using a Horizon W fan beam densitometer (Hologic Corporation) in the follow-up study. The two DXA machines were cross-calibrated using a spine phantom scanned 20 times on each. As required by the International Society for Clinical Densitometry (22) , the mean of 10 phantom scans before and after the change was calculated and the difference was ,1%. The follow-up scans were quantified using the comparison function. The coefficient of variation at the total hip was 1.2%, femoral neck 1.7%, lumbar spine 1.1%, and one-third distal forearm 1.3%. T-scores were generated from Hologic reference data (L1 to L4 spine/forearm) and the National Health and Nutrition Examination Survey (NHANES) III database (hip/femoral neck) (23) . Osteoporosis was defined as a T-score of 22.5 or less and osteopenia as a T-score of 21.0 to more than 22.5 (24) .
Data analysis
Data are presented as mean 6 SD, geometric mean (SD range) or, for nonnormally or non-log-normally distributed variables, median (interquartile range 
Results
Participant characteristics
We recruited 48 of the original 102 participants with T1D (47.1%; 20 males, 28 females) who attended for review a mean 6 SD of 10.3 6 0.4 years (range, 8.9 to 10.9 years) after the initial study. Compared with the 54 who were not recruited (27 were uncontactable or unable to attend because they had relocated, 19 declined participation, 5 were too unwell to attend, and 3 did not have BMD measured at both baseline and follow-up), the present participants had a similar age (39. The characteristics of the present participants at baseline and follow-up are summarized by sex in Table 1 . Their BMI had increased by an overall mean of 1.1 kg/m 2 at follow-up (P = 0.027) with a similar albeit nonsignificant mean increase by sex. The proportion of postmenopausal females had increased from approximately one-fifth to a half. Smoking status and the proportion who exercised remained unchanged at 10 years in both males and females, but alcohol consumption increased in the females. The daily insulin dose tended to decrease with time, consistent with the increase in the number of participants using pump therapy, especially females. There was no change in glycemia, but the urinary albumin/creatinine ratio decreased significantly in females, consistent with a more than doubling in the proportion taking angiotensinconverting enzyme inhibitors or angiotensin II receptor blockers. Serum creatinine concentrations increased significantly in females, and the proportion of females with an eGFR ,90 mL/min/1.73 m 2 tripled. Similar trends in renal function were also observed in males but did not reach statistical significance. There was no statistically significant increase in the proportion of participants with microvascular or macrovascular complications, although retinopathy was not included because of incomplete data.
No participants reported a diagnosis of osteoporosis, and none was taking antiresorptive therapy at baseline. One female started risedronate soon after the baseline assessment and continued to take it at follow-up, but no others reported taking antiresorptive therapy between baseline and the follow-up assessment. One female had polycystic ovarian syndrome, and there were single patients on a lowdose estrogen-containing oral contraceptive and on tibolone, but no other patients (female or male) were on hormone therapy. There were a number of self-reported fractures (see Table 1 ), and further details of these were ascertained from hospital medical records. There was one case of a female with an intertrochanteric hip fracture between assessments, but the other 12 were at sites other than neck of femur or vertebrae (2 upper limb, 5 lower limb, and 5 at other sites or multiple fractures) and were usually a result of significant trauma.
Bone mineral density
Changes in BMD and T-score are summarized by sex in Table 2 . The lowest baseline mean T-score in any group was at the femoral neck in the type 1 males. For males, after adjustment for age and BMI, there was a statistically significant increase in BMD and T-score at the lumbar spine during 10 years (P = 0.009; see Table 2 ) that remained significant after adjustment for log e (serum vitamin D) (P = 0.014). There was a similar but nonsignificant trend at the forearm but no change at the hip or femoral neck. Females exhibited no change in BMD or T-score at any site after adjustment for age, BMI, and postmenopausal status (P $ 0.09). Further adjustment for eGFR did not change the results of the analyses in males, but there was a weak but significant increase in BMD and T-score in females at the forearm (P = 0.046).
The mean 6 SD unadjusted changes in BMD at the femoral neck by sex are shown in Fig. 1 in a qualitative comparison with data from similar age groups from the NHANES III 1988 to 1994 (25) and from healthy, nonfractured, adult white females from Western Australia (no local equivalent data for males were available) (26) . Our sample of males had a lower mean BMD than did both the NHANES males and their female counterparts in the current study. The BMD did not reduce over 10 years in the males but fell in the present female sample in parallel with the comparator groups.
The relationship between change in (D) T-score at the femoral neck and categories of duration of T1D at followup (10 to 20 years, .20 to 30 years, and .30 years) in males is shown in Fig. 2 . There was no significant association between these two variables (P = 0.99), with participants in the first group who were relatively early in the course of their diabetes (mean duration 6 years at baseline) exhibiting a similar DT-score as the third group with long-duration diabetes (mean of 27 years at baseline).
The proportions of participants by sex who had osteoporosis, osteopenia, or a normal BMD at each time point are shown in Table 3 . Seven females who had normal BMD at the femoral neck at baseline had developed osteopenia by follow-up whereas one with osteopenia at the femoral neck at baseline had progressed to osteoporosis, a statistically significant change (P = 0.016). A similar but nonsignificant trend was also observed for females at the hip, but not the spine or forearm. No significant temporal changes were observed in males.
Biochemical and hormonal markers of bone metabolism
Changes in biochemical and hormonal markers of bone metabolism are summarized by sex in Table 4 . Serum ALP, CTX, and PTH did not change significantly during 10 years in either males or females, but there was a nonsignificant trend to a reduction in CTX in the males. Serum P1NP and serum osteocalcin declined significantly in males (both P = 0.001) but did not change in the females. Serum calcium and vitamin D concentrations increased significantly (P # 0.001) in parallel with increased percentages of participants taking calcium and vitamin D supplements at follow-up.
The effect of menopause in females
Because the onset of menopause may confound assessment of changes in BMD and bone turnover markers, females who were premenopausal (n = 14) or postmenopausal (n = 6) at both baseline and follow-up assessments were analyzed separately (see Table 5 ). Owing to the low numbers, age and BMI were not adjusted for in the analyses. As for all females, unadjusted reductions in BMD were statistically significant at the hip and femoral neck, whereas statistically significant unadjusted gains in BMD at the forearm were observed in premenopausal females. Serum calcium concentrations increased and P1NP decreased significantly in postmenopausal females, and CTX 
Discussion
The current study was prompted by our observation that community-based adult males with T1D have reduced BMD, especially at the femoral neck (14), with the possibility that further loss of skeletal calcium over time would put this group at substantially increased risk of fracture. In a representative subset approaching half of these patients restudied a mean of 10 years later, there had been no further reduction in BMD or T-scores after adjustment for age and BMI, and no increased risk of progression to osteopenia or osteoporosis. In females, who did not have a reduced BMD at baseline in the original study (14) , there was similarly no reduction in BMD or T-scores during 10 years after adjustment for age, BMI, and menopausal status, although there was an expected increased risk of progression to osteopenia or osteoporosis consistent with aging and menopause. These data suggest that reductions in BMD in males with T1D occur very early in the course of the disease but then stabilize. There have been other longitudinal studies of BMD in people with T1D, but none has involved follow up of as many participants for as long as 10 years. Miazgowski and Czekalski (27) found no change in BMD during 2 years at the lumbar spine, total body, or ultradistal radius in 54 adults with T1D. Campos Pastor et al. (28) also found no change in BMD at the femoral neck or lumbar spine in 62 adults with T1D followed up 7 years after initiation of intensive insulin therapy. A study of only seven patients followed for ;11 years found a small but significant 0.5% decline in bone mineral content (29) . In a study of 63 young women with T1D, those aged ,20 years experienced an increase in BMD during 2 years of follow-up that was similar to that in control subjects whereas BMD in the older women remained stable (30) . Another study in 41 young children with T1D found a deficit in bone size that normalized after a mean of 5.5 years of follow-up (31) . The results of these various studies do not contradict our findings, all suggesting that there is no sustained adverse effect of T1D on BMD. Our unexpected finding of a significant increase in BMD at the lumbar spine in our males with T1D likely reflects the poor reliability of BMD in the spine (32), which can be falsely elevated by factors such as degenerative disease and aortic calcification.
In males in the current study, there was a decrease in serum concentrations of bone formation markers (osteocalcin and P1NP) with the same directional albeit nonsignificant change in bone resorption (CTX). There were no equivalent temporal changes in the females. Although these data might suggest that there are sex differences in bone metabolism in T1D, biochemical tests of bone turnover show reductions over time in males in the general population whereas they are relatively stable in females in the age groups represented in the current study (33) . The increased use of calcium and vitamin D supplementation is unlikely to have influenced bone turnover markers (34) . The mild decline in renal function did not have an effect on ALP, the most sensitive marker of renal effects on bone turnover (35) . Although we did not measure bone-specific ALP, almost all total serum ALP concentrations were within normal limits (see Table 4 ) and no patients had a history of hepatobiliary disease.
Because T1D is associated with a significant increased risk of hip fracture, particularly after the age of 40 years (4-7, 36), we hypothesized that BMD would decline rapidly over the extended period of follow-up. There is, however, evidence that estimated hip fracture risk based on BMD correlates poorly with documented fractures in people with T1D (4), suggesting that factors other than BMD may be more important. Areal BMD measured by DXA does not capture structural bone changes, and prediction of bone fragility may be improved by measurement of bone microarchitecture (37, 38) . Reduced trabecular bone density and cortical thickness have been reported recently in a study of 95 children and adolescents with T1D (39). Shanbhogue et al. (40) found that adults with T1D and microvascular disease have reduced cortical and trabecular volumetric BMD as well as deterioration in bone microarchitecture. Verroken et al. (41) reported a decrease in cortical thickness and area as well as reduced trabecular volumetric BMD in adults with T1D compared with matched controls. These various recent studies suggest that bone fragility in T1D is due to microarchitectural decay, which is inadequately ascertained by conventional BMD measured by DXA.
Advanced glycation end products (AGEs) can accumulate in bone as a result of chronic hyperglycemia and increased oxidative stress, and data from animal studies suggest that AGEs increase the stiffness of the collagen network in bone, which may result in brittleness and increased bone fragility (3, (42) (43) (44) . Most human data regarding the effect of AGEs on bone quality are from studies in type 2 diabetes that have found an association between urine and/or serum pentosidine levels and an increased risk of vertebral fracture (3, 45, 46) . AGEs have also been implicated in the pathogenesis of microvascular disease. Epidemiologic studies and meta-analyses suggest that the presence of retinopathy, nephropathy, and neuropathy increases the risk of hip fracture in patients with T1D (4, 36), although there is evidence that microangiopathy complicating T1D reduces cortical and (40) . The present data suggest that these pathophysiological mechanisms are independent of BMD because the prevalence of microangiopathy increased during 10 years, especially nephropathy in females, without concomitant changes in BMD or T-scores, whereas the loss of skeletal calcium, which may complicate the early phases of T1D in males (probably in the first few years based on the data in Fig. 2 ), occurs well before chronic vascular complications can begin to develop. It is possible that this early decrease in BMD in males may be due to insulin deficiency, with subsequent slow improvement in BMD as a result of chronic insulin treatment. However, this explanation is inconsistent with the temporal BMD data in females. In our original study, we postulated that the males with T1D were older and had higher alcohol consumption than did the females, which may have contributed to a sex-specific lower BMD (14) . Additionally, most of the females were premenopausal, which may have been protective against initial skeletal calcium loss. A sex-specific difference in the changes in bone mineralization early in the course of T1D may, therefore, reflect a variety of factors.
A number of extraskeletal risk factors could account, at least in part, for the discrepancy between the increased risk of hip fracture in T1D and a minimal decline in BMD over a long period of follow-up. Patients with T1D may experience falls as a result of peripheral sensory neuropathy, autonomic neuropathy, visual impairment, and/ or hypoglycemia, which could increase risk of hip fracture without a direct effect on BMD (3-5, 8, 9) . Selfreported fractures increased during 10 years in both males and females in the current study but only one of these (a hip fracture in a female) was of the type classically associated with osteoporosis (neck of femur or vertebral compression fractures).
The current study had some limitations. The number of patients was relatively small but it was within the range of previous longitudinal studies in T1D (26) (27) (28) (29) (30) , and our duration of follow-up was one of the longest to date. There was change in densitometer between baseline and follow-up studies and, although the recommended cross-calibration was conducted, it is possible there was a difference in BMD measurement between the two scans. We relied on self-report to document prior fractures and then supplemented this information with available details from medical records. Although fracture data may have been incomplete as a result, the study was not designed to assess the relationship between BMD and skeletal failure.
BMD estimated by DXA remains a valuable tool in assessing the likelihood of fracture in older individuals, including as a key variable in risk prediction equations (47) . Our data and those of others (4) suggest, however, that BMD is likely to have a limited role in the context of younger individuals with T1D, a disease in which the high fracture rate may primarily reflect reduced bone quality. The present data highlight the need for studies of bone mineralization early in the course of T1D in males, as this seems to be when the reduction in BMD, especially at the neck of femur, occurs, perhaps as a result of the sex-specific effects of a period of insulin deficiency and poor metabolic control.
